As the novel coronavirus spread throughout China, it became clear that a key piece of protective equipment for health care workers was the N95 respirator mask.
Maplewood-based 3M, as the largest maker of N95s, kicked into high gear to make as many as possible at its Shanghai plant, nine hours east of Wuhan — the epicenter of the disease in China.
As the coronavirus mushroomed across the rest of the world, a global shortage of N95s would develop and test 3M like nothing else in its 118-year history.
Entering the year, only 15% of 3M's N95s were made for health care customers. Not even four months later, it's now 90%. That "flip" was done at the same time 3M raced to quadruple production rates, said Denise Rutherford, 3M's senior vice president for corporate affairs.
The dash to ramp up production involved opening idled production lines and finding factory workers to get them going. It meant overcoming regulatory and trade barriers, changing supply chains on the fly and reconfiguring its distribution.
It wasn't all smooth — from the operational or public relations standpoints. 3M had to navigate a political firestorm when President Donald Trump decided it was not working fast enough to achieve U.S. needs.
Yet industry watchers are lauding 3M as handling it particularly well, even as it was dealing with cratering demand for other stalwart lines such as automotive and industrial products as the economy slowed to unprecedented levels amid the fight to stop COVID-19's spread.
Coming off a tough year, 3M's financials are expected to show the same effects seen by other big global companies when 3M reports first-quarter results Tuesday.